For over 30 years, all our resources have been channeled in a single direction: to provide innovative medical dermatological solutions that meet the needs of patients and physicians with a particular focus on acne, rosacea, psoriasis and other steroid-responsive dermatoses, onychomycosis (fungal nail infections), pigmentary disorders, skin cancer and medical aesthetic and corrective solutions for skin senescence. The skin conditions we treat can have strong psychological and social implications in the everyday lives of our patients. By treating these conditions, we help people preserve, restore and maintain healthy skin and improve their quality of life. Today, Galderma is a global dermatology company partnering with healthcare professionals to provide innovative medical solutions to patients with skin health needs. The company has 34 wholly-owned affiliates and a worldwide network of distributors, over 6 000 employees and an extensive product portfolio available in more than 100 countries.
Parent Company
Lausanne, CH
Galderma was founded in 1981 and is headquartered in Lausanne, CH
Report incorrect company information

Galderma Office Locations

Galderma has an office in Lausanne
Lausanne, CH (HQ)
2 Avenue Gratta-Paille
Show all (1)
Report incorrect company information

Galderma Financials and Metrics

Summary Metrics

Founding Date

Galderma is a subsidiary of Nestle
Report incorrect company information

Galderma News and Updates

Plastic Surgery Products Global Market 2018: Key Players – Cynosure, DePuy Synthes, Galderma, Syneron Medical, Stryker

Plastic Surgery Products -Market Demand, Growth, Opportunities and Analysis of Top Key Player Forecast to 2023 Posted via Industry Today. Follow us on Twitter @IndustryToday

Facial Injectables Market to Surpass US$ 17.2 Billion by 2025

Facial injectables market to surpass US$ 17.2 billion by 2025 with increasing focus on aesthetic beauty Posted via Industry Today. Follow us on Twitter @IndustryToday

Actinic Keratosis Market: A Straight Survey of Growth Factors and Expected Projection 2017 – 2025

The actinic keratosis market was valued at USD 6,847.2 Mn in 2016 and is expected to reach USD 9,416.1 Mn by 2025, with the market progressing at a CAGR 4.35%from 2017-2025. Posted via Industry Today. Follow us on Twitter @IndustryToday
Report incorrect company information